171 related articles for article (PubMed ID: 37157016)
1. A novel lncRNA SNHG29 regulates EP300- related histone acetylation modification and inhibits FLT3-ITD AML development.
Liu S; Zhou J; Ye X; Chen D; Chen W; Lin Y; Chen Z; Chen B; Shang J
Leukemia; 2023 Jul; 37(7):1421-1434. PubMed ID: 37157016
[TBL] [Abstract][Full Text] [Related]
2. IGF2BP2 promotes lncRNA DANCR stability mediated glycolysis and affects the progression of FLT3-ITD + acute myeloid leukemia.
Wu S; Chi C; Weng S; Zhou W; Liu Z
Apoptosis; 2023 Aug; 28(7-8):1035-1047. PubMed ID: 37060505
[TBL] [Abstract][Full Text] [Related]
3. circMYBL2, a circRNA from MYBL2, regulates FLT3 translation by recruiting PTBP1 to promote FLT3-ITD AML progression.
Sun YM; Wang WT; Zeng ZC; Chen TQ; Han C; Pan Q; Huang W; Fang K; Sun LY; Zhou YF; Luo XQ; Luo C; Du X; Chen YQ
Blood; 2019 Oct; 134(18):1533-1546. PubMed ID: 31387917
[TBL] [Abstract][Full Text] [Related]
4. The FLT3 internal tandem duplication mutation is a secondary target of the aurora B kinase inhibitor AZD1152-HQPA in acute myelogenous leukemia cells.
Grundy M; Seedhouse C; Shang S; Richardson J; Russell N; Pallis M
Mol Cancer Ther; 2010 Mar; 9(3):661-72. PubMed ID: 20159992
[TBL] [Abstract][Full Text] [Related]
5. FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia.
Long J; Jia MY; Fang WY; Chen XJ; Mu LL; Wang ZY; Shen Y; Xiang RF; Wang LN; Wang L; Jiang CH; Jiang JL; Zhang WJ; Sun YD; Chang L; Gao WH; Wang Y; Li JM; Hong DL; Liang AB; Hu J
Blood; 2020 Apr; 135(17):1472-1483. PubMed ID: 32315388
[TBL] [Abstract][Full Text] [Related]
6. ULK1 inhibition as a targeted therapeutic strategy for FLT3-ITD-mutated acute myeloid leukemia.
Hwang DY; Eom JI; Jang JE; Jeung HK; Chung H; Kim JS; Cheong JW; Min YH
J Exp Clin Cancer Res; 2020 May; 39(1):85. PubMed ID: 32393312
[TBL] [Abstract][Full Text] [Related]
7. PRMT1-mediated FLT3 arginine methylation promotes maintenance of FLT3-ITD
He X; Zhu Y; Lin YC; Li M; Du J; Dong H; Sun J; Zhu L; Wang H; Ding Z; Zhang L; Zhang L; Zhao D; Wang Z; Wu H; Zhang H; Jiang W; Xu Y; Jin J; Shen Y; Perry J; Zhao X; Zhang B; Liu S; Xue SL; Shen B; Chen CW; Chen J; Khaled S; Kuo YH; Marcucci G; Luo Y; Li L
Blood; 2019 Aug; 134(6):548-560. PubMed ID: 31217189
[TBL] [Abstract][Full Text] [Related]
8. Independent oncogenic and therapeutic significance of phosphatase PRL-3 in FLT3-ITD-negative acute myeloid leukemia.
Qu S; Liu B; Guo X; Shi H; Zhou M; Li L; Yang S; Tong X; Wang H
Cancer; 2014 Jul; 120(14):2130-41. PubMed ID: 24737397
[TBL] [Abstract][Full Text] [Related]
9. GATM-Mediated Creatine Biosynthesis Enables Maintenance of FLT3-ITD-Mutant Acute Myeloid Leukemia.
Zhang Y; Newsom KJ; Zhang M; Kelley JS; Starostik P
Mol Cancer Res; 2022 Feb; 20(2):293-304. PubMed ID: 34635505
[TBL] [Abstract][Full Text] [Related]
10. Combined inhibition of Notch and FLT3 produces synergistic cytotoxic effects in FLT3/ITD
Li D; Li T; Shang Z; Zhao L; Xu Q; Tan J; Qin Y; Zhang Y; Cao Y; Wang N; Huang L; Zhu X; Zhou K; Chen L; Li C; Xie T; Yang Y; Wang J; Zhou J
Signal Transduct Target Ther; 2020 Mar; 5(1):21. PubMed ID: 32296014
[TBL] [Abstract][Full Text] [Related]
11. SRC is a signaling mediator in FLT3-ITD- but not in FLT3-TKD-positive AML.
Leischner H; Albers C; Grundler R; Razumovskaya E; Spiekermann K; Bohlander S; Rönnstrand L; Götze K; Peschel C; Duyster J
Blood; 2012 Apr; 119(17):4026-33. PubMed ID: 22411868
[TBL] [Abstract][Full Text] [Related]
12. CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia.
Bertoli S; Boutzen H; David L; Larrue C; Vergez F; Fernandez-Vidal A; Yuan L; Hospital MA; Tamburini J; Demur C; Delabesse E; Saland E; Sarry JE; Galcera MO; Mansat-De Mas V; Didier C; Dozier C; Récher C; Manenti S
Oncotarget; 2015 Nov; 6(35):38061-78. PubMed ID: 26515730
[TBL] [Abstract][Full Text] [Related]
13. Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AML.
Sallmyr A; Fan J; Datta K; Kim KT; Grosu D; Shapiro P; Small D; Rassool F
Blood; 2008 Mar; 111(6):3173-82. PubMed ID: 18192505
[TBL] [Abstract][Full Text] [Related]
14. Melatonin enhances sorafenib-induced cytotoxicity in FLT3-ITD acute myeloid leukemia cells by redox modification.
Tian T; Li J; Li Y; Lu YX; Tang YL; Wang H; Zheng F; Shi D; Long Q; Chen M; Garcia-Manero G; Hu Y; Qin L; Deng W
Theranostics; 2019; 9(13):3768-3779. PubMed ID: 31281512
[TBL] [Abstract][Full Text] [Related]
15. Oncogenic FLT3-ITD supports autophagy via ATF4 in acute myeloid leukemia.
Heydt Q; Larrue C; Saland E; Bertoli S; Sarry JE; Besson A; Manenti S; Joffre C; Mansat-De Mas V
Oncogene; 2018 Feb; 37(6):787-797. PubMed ID: 29059168
[TBL] [Abstract][Full Text] [Related]
16. Nuclear factor of activated T-cells, NFATC1, governs FLT3
Solovey M; Wang Y; Michel C; Metzeler KH; Herold T; Göthert JR; Ellenrieder V; Hessmann E; Gattenlöhner S; Neubauer A; Pavlinic D; Benes V; Rupp O; Burchert A
J Hematol Oncol; 2019 Jul; 12(1):72. PubMed ID: 31286998
[TBL] [Abstract][Full Text] [Related]
17. NFATc1 as a therapeutic target in FLT3-ITD-positive AML.
Metzelder SK; Michel C; von Bonin M; Rehberger M; Hessmann E; Inselmann S; Solovey M; Wang Y; Sohlbach K; Brendel C; Stiewe T; Charles J; Ten Haaf A; Ellenrieder V; Neubauer A; Gattenlöhner S; Bornhäuser M; Burchert A
Leukemia; 2015 Jul; 29(7):1470-7. PubMed ID: 25976987
[TBL] [Abstract][Full Text] [Related]
18. Targeting FLT3-ITD signaling mediates ceramide-dependent mitophagy and attenuates drug resistance in AML.
Dany M; Gencer S; Nganga R; Thomas RJ; Oleinik N; Baron KD; Szulc ZM; Ruvolo P; Kornblau S; Andreeff M; Ogretmen B
Blood; 2016 Oct; 128(15):1944-1958. PubMed ID: 27540013
[TBL] [Abstract][Full Text] [Related]
19. Proteasome inhibitors induce FLT3-ITD degradation through autophagy in AML cells.
Larrue C; Saland E; Boutzen H; Vergez F; David M; Joffre C; Hospital MA; Tamburini J; Delabesse E; Manenti S; Sarry JE; Récher C
Blood; 2016 Feb; 127(7):882-92. PubMed ID: 26286850
[TBL] [Abstract][Full Text] [Related]
20. FLT3-ITD cooperates with Rac1 to modulate the sensitivity of leukemic cells to chemotherapeutic agents via regulation of DNA repair pathways.
Wu M; Li L; Hamaker M; Small D; Duffield AS
Haematologica; 2019 Dec; 104(12):2418-2428. PubMed ID: 30975911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
